OBJECTIVES: To report on complications from transrectal ultrasound-guided insertion of fiducial markers for prostate image-guided radiotherapy. METHODS: 234 patients who underwent transrectal fiducial marker insertion for prostate cancer image-guided radiotherapy were assessed retrospectively by questionnaire with regard to the duration and severity of eight symptoms experienced following the procedure. Pain during the implantation procedure was assessed according to the Wong-Baker faces pain scale. RESULTS: Of 234 patients, 32% had at least one new symptom after the procedure. The commonest new symptom following the procedure was urinary frequency affecting 16% of patients who had not been troubled by frequency beforehand. Haematuria, rectal bleeding, dysuria and haematospermia affected 9-13% of patients, mostly at Grade 1 or 2. Pain, obstruction, and fever and shivers affected 3-4% of patients. Grade 3 rectal bleeding, haematuria, fever and shivers, and urinary frequency affected 0.5-1.5% of patients. Only one patient had a Grade 4 complication (i.e. fever and shivers). Overall, 9% of patients had symptoms lasting more than 2 weeks. The commonest symptoms that lasted more than 2 weeks were frequency, dysuria, obstructive symptoms and rectal bleeding. Mean pain score during the procedure was 1.1 (range 0-5). CONCLUSION: Transrectal ultrasound-guided fiducial marker insertion for image-guided radiotherapy is well tolerated in the majority of prostate cancer patients. Most symptoms were Grade 1 or 2 in severity. Symptoms in the majority of patients last under 2 weeks. The most serious complication was sepsis in our study.
OBJECTIVES: To report on complications from transrectal ultrasound-guided insertion of fiducial markers for prostate image-guided radiotherapy. METHODS: 234 patients who underwent transrectal fiducial marker insertion for prostate cancer image-guided radiotherapy were assessed retrospectively by questionnaire with regard to the duration and severity of eight symptoms experienced following the procedure. Pain during the implantation procedure was assessed according to the Wong-Baker faces pain scale. RESULTS: Of 234 patients, 32% had at least one new symptom after the procedure. The commonest new symptom following the procedure was urinary frequency affecting 16% of patients who had not been troubled by frequency beforehand. Haematuria, rectal bleeding, dysuria and haematospermia affected 9-13% of patients, mostly at Grade 1 or 2. Pain, obstruction, and fever and shivers affected 3-4% of patients. Grade 3 rectal bleeding, haematuria, fever and shivers, and urinary frequency affected 0.5-1.5% of patients. Only one patient had a Grade 4 complication (i.e. fever and shivers). Overall, 9% of patients had symptoms lasting more than 2 weeks. The commonest symptoms that lasted more than 2 weeks were frequency, dysuria, obstructive symptoms and rectal bleeding. Mean pain score during the procedure was 1.1 (range 0-5). CONCLUSION: Transrectal ultrasound-guided fiducial marker insertion for image-guided radiotherapy is well tolerated in the majority of prostate cancerpatients. Most symptoms were Grade 1 or 2 in severity. Symptoms in the majority of patients last under 2 weeks. The most serious complication was sepsis in our study.
Authors: John M Schallenkamp; Michael G Herman; Jon J Kruse; Thomas M Pisansky Journal: Int J Radiat Oncol Biol Phys Date: 2005-11-01 Impact factor: 7.038
Authors: Michael S Ingber; Ibrahim Ibrahim; Cynthia Turzewski; Jay B Hollander; Ananias C Diokno Journal: Int Urol Nephrol Date: 2009-08-08 Impact factor: 2.370
Authors: B Djavan; M Waldert; A Zlotta; P Dobronski; C Seitz; M Remzi; A Borkowski; C Schulman; M Marberger Journal: J Urol Date: 2001-09 Impact factor: 7.450
Authors: David M Livermore; Dorothy James; Mark Reacher; Catriona Graham; Thomas Nichols; Peter Stephens; Alan P Johnson; Robert C George Journal: Emerg Infect Dis Date: 2002-05 Impact factor: 6.883
Authors: Aart J Nederveen; Homan Dehnad; Uulke A van der Heide; R Jeroen A van Moorselaar; Pieter Hofman; Jan J W Lagendijk Journal: Radiother Oncol Date: 2003-07 Impact factor: 6.280
Authors: Andreas P Berger; Ferdinand Frauscher; Ethan J Halpern; Robert Spranger; Hannes Steiner; Georg Bartsch; Wolfgang Horninger Journal: Urology Date: 2003-03 Impact factor: 2.649
Authors: Jasmin Loh; Katie Baker; Swetha Sridharan; Peter Greer; Chris Wratten; Anne Capp; Sarah Gallagher; Jarad Martin Journal: Radiat Oncol Date: 2015-02-13 Impact factor: 3.481